Akebia Therapeutics, Inc.
AKBA Healthcare Drug Manufacturers Specialty & Generic
Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS fell 3,433.3%, free cash flow fell 89.0% and total debt rose 5.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AKBA
Akebia Therapeutics, Inc. (AKBA) EV/Sales
As of 16 October 2026, Akebia Therapeutics, Inc. (AKBA) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −0.3× (December 2018) to 4.8× (June 2020); the current reading is higher than 34% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (50.63%) |
| FY2024 | 2.5× | 114.18% |
| FY2023 | 1.2× | 288.33% |
| FY2022 | 0.3× | (84.29%) |
| FY2021 | 1.9× | 118.73% |
| FY2020 | 0.9× | (56.52%) |
| FY2019 | 2.0× | 82.72% |
| FY2018 | 1.1× | (39.48%) |
| FY2017 | 1.8× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (17.02%) |
| Mar 2026 | 1.1× | (11.29%) |
| Dec 2025 | 1.2× | (54.78%) |
| Sep 2025 | 2.8× | (36.28%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −9.7× |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| ORGO Organogenesis compare | 0.2× |
| AKBA Akebia Therapeutics, Inc. | 0.3× |
| ACB Aurora Cannabis Inc. compare | 0.9× |
| DERM Journey Medical Corporation compare | 2.0× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| LFCR Lifecore Biomedical, Inc. compare | 3.4× |
| SIGA Siga Technologies Inc. compare | 5.0× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)